CLCM
AERI

Crawford Lake Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

Crawford Lake Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-47,847
Closed -$2.51M – 138
2017
Q2 		$2.51M Buy
+47,847
New +$2.23M 0.56% 56
2017
Q1 		– Sell
-7,439
Closed -$282K – 88
2016
Q4 		$282K Buy
+7,439
New +$281K 0.2% 37

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Crawford Lake Capital Management's AERI Position: Q3 2017 in Review

Crawford Lake Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2017, closing a stake of 47,847 shares — an estimated $2.51M sold.

Crawford Lake Capital Management first reported a position in AERI in Q4 2016 and held it in 2 quarters. The position peaked at $2.51M in Q2 2017. 182 funds tracked by Wall St. Rank hold AERI as of Q3 2017.

  • Crawford Lake Capital Management reported no remaining Aerie Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Crawford Lake Capital Management sold 47,847 Aerie Pharmaceuticals shares in Q3 2017, an estimated $2.51M.
  • Crawford Lake Capital Management first reported a position in Aerie Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Crawford Lake Capital Management's Aerie Pharmaceuticals position peaked at $2.51M in Q2 2017.
  • 182 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2017.

Based on Crawford Lake Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.